Dermatology Medical News about Ligustrazine; tumor metastasis; angiogenesis; VEGF

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by vascular endothelial growth factor
Biochemical and Biophysical Research Communications, 07/20/09

Chen L et al. - In a study to investigate anti-angiogenic properties of ligustrazine in a series of in vitro and in vivo models, data suggest that ligustrazine may inhibit tumor metastasis, at least in part, through its anti-angiogenic activity.

Methods

Angiogenesis is crucial for tumor metastasis, with many compounds that inhibit tumor metastasis acting through suppression of angiogenesis.

Results

Ligustrazine inhibited VEGF-induced human umbilical vein endothelial cell (HUVEC) migration and tube formation in a dose-dependent manner in vitro, and had limited cytotoxicity to HUVECs and normal fibroblasts even at a dose up to 100 μg/ml.
Ligustrazine suppressed VEGF-induced rat aortic ring sprouting dose-dependently.
In vivo, ligustrazine reduced the Hb content in a matrigel plug implanted in mice and inhibited new vessel formation in CAM.
In a B16F10 spontaneous metastasis model, ligustrazine decreased expression of CD34 and VEGF in primary tumor tissue and reduced the number of metastasis nodi on the lung surface.

<< Previous
Dermal mucinosis as a sign of venous insufficiency

Next >>
Cost-effectiveness of anti-retroviral therapy at a district...